Divergence, not diversity of an attenuated equine lentivirus vaccine strain correlates with protection from disease

Vaccine

Volumn 28, Issue 51, 2010, Pages 8095-8104

  Craigo, Jodi K ^a,b   Barnes, Shannon ^a,b   Cook, Sheila J ^c   Issel, Charles J ^c   Montelaro, Ronald C ^a,b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Attenuated; EIAV; Vaccine

Indexed keywords

EQUINE LENTIVIRUS VACCINE; LIVE VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; EVOLUTION; FEMALE; IMMUNITY; MALE; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS STRAIN;

ANIMALS; CLUSTER ANALYSIS; EQUINE INFECTIOUS ANEMIA; EVOLUTION, MOLECULAR; FEMALE; HORSE DISEASES; HORSES; INFECTIOUS ANEMIA VIRUS, EQUINE; MALE; PHYLOGENY; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; SEQUENCE HOMOLOGY; VACCINES, ATTENUATED; VIRAL VACCINES;

EID: 78649646559     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.10.003     Document Type: Article

References (71)

1. Craigo J.K., Zhang B., Barnes S., Tagmyer T.L., Cook S.J., Issel C.J., et al. Envelope variation as a primary determinant of lentiviral vaccine efficacy. Proc Natl Acad Sci 2007, 104(38):15105-15110.
2. Hambleton S. Prevention of varicella and zoster by live attenuated VZV vaccine. Front Biosci 2008, 13:2696-2704.
3. Melink J.A., Plotkin S.A., Mortimer E.A., Saunders W.B. Vaccines 1994, Academic, SanDiego.
4. Mims C.A. The Pathogenesis of infectious diseases 1987, Academic, SanDiego.
5. Reynolds M.R., Weiler A.M., Weisgrau K.L., Piaskowski S.M., Furlott J.R., Weinfurter J.T., et al. Macaques vaccinated with live-attenuated SIV control replication of heterologous virus. J Exp Med 2008, 205(11):2537-2550.
6. Whitney J.B., Ruprecht R.M. Live attenuated HIV vaccines: pitfalls and prospects. Curr Opin Infect Dis 2004, 17(1):17-26.
7. Berkhout B., Verhoef K., van Wamel J.L.B., Back N.K.T. Genetic instability of live-attenuated human immunodeficiency virus type 1 vaccine strains. J Virol 1999, 73(2):1138-1145.
8. Das A.T., Baldwin C.E., Vink M., Berkhout B. Improving the safety of a conditional-live human immunodeficiency virus type 1 vaccine by controlling both gene expression and cell entry. J Virol 2005, 79(6):3855-3858.
9. Baba T.W., Liska V., Khimani A.H., Ray N.B., Dailey P.J., Penninck D., et al. Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques. Nat Med 1999, 5(2):194-203.
10. Kumar A., Liu Z., Sheffer D., Smith M., Singh D.K., Buch S., et al. Protection of macaques against AIDS with a live attenuated SHIV vaccine is of finite duration. Virology 2008, 371(2):238-245.
11. Harrold S.M., Cook S.J., Cook R.F., Rushlow K.E., Issel C.J., Montelaro R.C. Tissue sites of persistent infection and active replication of equine infectious anemia virus during acute disease and asymptomatic infection in experimentally infected equids. J Virol 2000, 74(7):3112-3121.
12. Hammond S.A., Li F., McKeon B.M., Cook S.J., Issel C.J., Montelaro R.C. Immune responses and viral replication in long-term inapparent carrier ponies inoculated with equine infectious anemia virus. J Virol 2000, 74(13):5968-5981.
13. Craigo J.K., Montelaro R.C. Equine infectious anemia virus (retroviridae). Encyclopedia of virology 2008, Academic Press, p. 167-74. Third ed.
14. Montelaro R.C., Ball J.M., Rushlow K. Equine retroviruses. The retroviridae 1993, 257-360. Plenum Press, New York, NY. J.A. Levy (Ed.).
15. Kono Y., hirasawa K., Fukunaga Y., Taniguchi T. Recrudesence of equine infectious anemia by treatment with immunosuppressive drugs. Nat Inst Anim Health Quart 1976, 16:8-15.
16. Craigo J.K., Leroux C., Howe L., Steckbeck J.D., Cook S.J., Issel C.J., et al. Transient immune suppression of inapparent carriers infected with a principal neutralizing domain-deficient equine infectious anaemia virus induces neutralizing antibodies and lowers steady-state virus replication. J Gen Virol 2002, 83(6):1353-1359.
17. Craigo J.K., Sturgeon T.J., Cook S.J., Issel C.J., Leroux C., Montelaro R.C. Apparent elimination of EIAV ancestral species in a long-term inapparent carrier. Virology 2006, 344(2):340-353.
18. Craigo J.K., Durkin S., Sturgeon T.J., Tagmyer T., Cook S.J., Issel C.J., et al. Immune suppression of challenged vaccinates as a rigorous assessment of sterile protection by lentiviral vaccines. Vaccine 2007, 25(5):834-845.
19. Craigo J.K., Li F., Steckbeck J.D., Durkin S., Howe L., Cook S.J., et al. Discerning an effective balance between equine infectious anemia virus attenuation and vaccine efficacy. J Virol 2005, 79(5):2666-2677.
20. Li F., Craigo J.K., Howe L., Steckbeck J.D., Cook S., Issel C., et al. A live attenuated equine infectious anemia virus proviral vaccine with a modified S2 gene provides protection from detectable infection by intravenous virulent virus challenge of experimentally inoculated horses. J Virol 2003, 77(13):7244-7253.
21. Raabe M.L., Issel C.J., Cook S.J., Cook R.F., Woodson B., Montelaro R.C. Immunization with a recombinant envelope protein (rgp90) of EIAV produces a spectrum of vaccine efficacy ranging from lack of clinical disease to severe enhancement. Virology 1998, 245:151-162.
22. Wang S.Z., Rushlow K.E., Issel C.J., Cook R.F., Cook S.J., Raabe M.L., et al. Enhancement of EIAV replication and disease by immunization with a baculovirus-expressed recombinant envelope surface glycoprotein. Virology 1994, 199:247-251.
23. Issel C.J., Horohov D.W., Lea D.F., Adams W.V., Hagius S.D., McManus J.M., et al. Efficacy of inactivated whole-virus and subunit vaccines in preventing infection and disease caused by equine infectious anemia virus. J Virol 1992, 66:3398-3408.
24. Hammond S.A., Cook S.J., Falo L.D., Issel C.J., Montelaro R.C. A particulate viral protein vaccine reduces viral load and delays progression to disease in immunized ponies challenged with equine infectious anemia virus. Virology 1999, 254:37-49.
25. Koff W.C., Johnson P.R., Watkins D.I., Burton D.R., Lifson J.D., Hasenkrug K.J., et al. HIV vaccine design: insights from live attenuated SIV vaccines. Nat Immunol 2006, 7(1):19-23.
26. Montelaro R.C., Wigzell H. Vaccines and immunology: overview. AIDS 1995, 9(Suppl A):S111-S112.
27. Uhl E.W., Heaton-Jones T.G., Pu R., Yamamoto J.K. FIV vaccine development and its importance to veterinary and human medicine: a review. FIV vaccine 2002 update and review. Vet Immunol Immunopathol 2002, 90(3-4):113-132.
28. Mills J., Desrosiers R.C., Rud E., Almond N. Live attenuated HIV vaccines: a proposal for further research and development. AIDS Res Hum Retroviruses 2000, 16(15):1453-1461.
29. Tagmyer T.L., Craigo J.K., Cook S.J., Even D.L., Issel C.J., Montelaro R.C. Envelope determinants of equine infectious anemia virus vaccine protection and the effects of sequence variation on immune recognition. J Virol 2008, 82(8):4052-4063.
30. Tagmyer T.L., Craigo J.K., Cook S.J., Issel C.J., Montelaro R.C. Envelope-specific T-helper and cytotoxic T-lymphocyte responses associated with protective immunity to equine infectious anemia virus. J Gen Virol 2007, 88(Pt 4):1324-1336.
31. Craigo J.K., Montelaro R.C. EIAV envelope diversity: shaping viral persistence and encumbering vaccine efficacy. Curr HIV Res 2010, 8(1):81-86.
32. † infections. J Virol 1998, 72(10):7852-7859.
33. Montelaro R.C., Cole K.S., Hammond S.A. Maturation of immune responses to lentivirus infection: implications for AIDS vaccine development. AIDS Res Hum Retroviruses 1998, 14(Suppl 3):S255-S259.
34. Johnson R.P., Desrosiers R.C. Protective immunity induced by live attenuated simian immunodeficiency virus. Curr Opin Immunol 1998, 10(4):436-443.
35. Johnson R.P., Lifson J.D., Czajak S.C., Cole K.S., Manson K.H., Glickman R., et al. Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: inverse relationship of degree of protection with level of attenuation. J Virol 1999, 73(6):4952-4961.
36. Johnson R.P. Live attenuated AIDS vaccines: hazards and hopes. Nat Med 1999, 5(2):154-155.
37. Leroux C., Issel C., Montelaro R.C. Novel and dynamic evolution of equine infectious anemia virus genomic quasispecies associated with sequential disease cycles in an experimentally infected pony. J Virol 1997, 71(12):9627-9639.
38. Lichtenstein D.L., Issel C.J., Montelaro R.C. Genomic quasispecies associated with the initiation of infection and disease in ponies experimentally infected with equine infectious anemia virus. J Virol 1996, 70(6):3346-3354.
39. Payne S.L., Rausch J., Rushlow K., Montelaro R.C., Issel C., Flaherty M., et al. Characterization of infectious molecular clones of equine infectious anaemia virus. J Gen Virol 1994, 75(Pt 2):425-429. (Chaoping file 4-2).
40. Rwambo P.M., Issel C.J., Hussain K.A., Montelaro R.C. In vitro isolation of a neutralization escape mutant of equine infectious anemia virus (EIAV). Arch Virol 1990, 111:275-280.
41. Hammond S.A., Cook S.J., Lichtenstein D.L., Issel C.J., Montelaro R.C. Maturation of the cellular and humoral immune responses to persistent infection in horses by equine infectious anemia virus is a complex and lengthy process. J Virol 1997, 71(5):3840-3852.
42. Leroux C., Craigo J.K., Issel C.J., Montelaro R.C. Equine infectious anemia virus genomic evolution in progressor and nonprogressor ponies. J Virol 2001, 75(10):4570-4583.
43. Cook R.F., Cook S.J., Li F.L., Montelaro R.C., Issel C.J. Development of a multiplex real-time reverse transcriptase-polymerase chain reaction for equine infectious anemia virus (EIAV). J Virol Methods 2002, 105(1):171-179.
44. Drummond A., Ashton B., Cheung M., Heled J., Kearse M., Moir R., et al. Geneious version 4. 7 2009, Available from http://www.geneious.com.
45. Dayhoff M.O., Schwartz R.M., Orcutt B.C., Dayhoff M.O. A model of evolutionary change in proteins. Matrices for detecting distant relationships. Atlas of protein sequence and structure 1978, vol. 5. National biomedical research foundation, Washington, D.C, p. 345-58.
46. Swofford D.L. PAUP: phylogenetic analysis using parsimony and other methods 2001, Sinauer Associates, Sunderlan, MA.
47. Morariu V., Srinivasan B., Raykar V., Duraiswami R., Davis L. Automatic online tuning for fast Gaussian summation. Adv Neural Inform Process Syst 2008, 21:1113-1120.
48. Li F., Leroux C., Craigo J.K., Cook S.J., Issel C.J., Montelaro R.C. The S2 gene of equine infectious anemia virus is a highly conserved determinant of viral replication and virulence properties in experimentally infected ponies. J Virol 2000, 74(1):573-579.
49. Li F., Puffer B.A., Montelaro R.C. The S2 gene of equine infectious anemia virus is dispensable for viral replication in vitro. J Virol 1998, 72:8344-8348.
50. Payne S.L., Rushlow K., Dhruva B.R., Issel C.J., Montelaro R.C. Localization of conserved and variable antigenic domains of equine infectious anemia virus envelope glycoproteins using recombinant env-encoded protein fragments produced in Escherichia coli. Virology 1989, 172:609-615.
51. Craigo J.K., Barnes S., Zhang B., Cook S.J., Howe L., Issel C.J., et al. An EIAV field isolate reveals much higher levels of subtype variability than currently reported for the equine lentivirus family. Retrovirology 2009, 6:95.
52. Zheng Y.H., Nakaya T., Sentsui H., Kameoka M., Kishi M., Hagiwara K., et al. Insertions, duplications and substitutions in restricted gp90 regions of equine infectious anemia virus during febrile episodes in an experimentally infected horse. J Gen Virol 1997, 78:807-820.
53. Zheng Y.H, Sentsui H., Nakaya T., Kono Y., Ikuta K. In vivo dynamics of equine infectious anemia viruses emerging during febrile episodes: insertions/duplications at the principal neutralizing domain. J Virol 1997, 71(7):5031-5039.
54. Bogers W.M., Cheng-Mayer C., Montelaro R.C. Developments in preclinical AIDS vaccine efficacy models. AIDS 2000, 14(Suppl 3):S141-S145.
55. Blower S.M., Koelle K., Kirschner D.E., Mills J. Live attenuated HIV vaccines: predicting the tradeoff between efficacy and safety. Proc Natl Acad Sci 2001, 98(6):3618.
56. Almond N., Stott J. Live attenuated SIV-a model of a vaccine for AIDS. Immunol Lett 1999, 66(1-3):167-170.
57. Shen R.X., Wang Z. Development and use of an equine infectious anemia donkey leucocyte attenuated vaccine. EIAV: a national review of policies, programs, and future objectives 1985.
58. Kumar A., Mukherjee S., Shen J., Buch S., Li Z., Adany I., et al. Immunization of macaques with live simian human immunodeficiency virus (shiv) vaccines conferred protection against aids induced by homologous and heterologous SHIVs and simian immunodeficiency virus. Virology 2002, 301(2):189-205.
59. Amara R.R., Patel K., Niedziela G., Nigam P., Sharma S., Staprans S.I., et al. A combination DNA and attenuated simian immunodeficiency virus vaccine strategy provides enhanced protection from simian/human immunodeficiency virus-induced disease. J Virol 2005, 79(24):15356-15367.
60. Busch M., Abel K., Li J., Piatak, L.J.D., Miller C.J. Efficacy of a SHIV 89. 6 proviral DNA vaccine against mucosal SIVmac239 challenge. Vaccine 2005, 23(31):4036-4047.
61. Abel K., Compton L., Rourke T., Montefiori D., Lu D., Rothaeusler K., et al. Simian-human immunodeficiency virus SHIV89.6-induced protection against intravaginal challenge with pathogenic SIVmac239 is independent of the route of immunization and is associated with a combination of cytotoxic T-lymphocyte and alpha interferon responses. J Virol 2003, 77(5):3099-3118.
62. Stahl-Hennig C., Dittmer U., Nisslein T., Pekrun K., Petry H., Jurkiewicz E., et al. Attenuated SIV imparts immunity to challenge with pathogenic spleen-derived SIV but cannot prevent repair of the nef deletion. Immunol Lett 1996, 51(1-2):129-135.
63. Kirchhoff F., Kestler H.W., Desrosiers R.C. Upstream U3 sequences in simian immunodeficiency virus are selectively deleted in vivo in the absence of an intact nef gene. J Virol 1994, 68(3):2031-2037.
64. Churchill M.J., Rhodes D.I., Learmont J.C., Sullivan J.S., Wesselingh S.L., Cooke I.R.C., et al. Longitudinal analysis of human immunodeficiency virus type 1 nef/long terminal repeat sequences in a cohort of long-term survivors infected from a single source. J Virol 2006, 80(2):1047-1052.
65. Munch J., Stolte N., Fuchs D., Stahl-Hennig C., Kirchhoff F. Efficient class I major histocompatibility complex down-regulation by simian immunodeficiency virus nef is associated with a strong selective advantage in infected rhesus macaques. J Virol 2001, 75(21):10532-10536.
66. Alexander L., Illyinskii P.O., Lang S.M., Means R.E., Lifson J., Mansfield K., et al. Determinants of increased replicative capacity of serially passaged simian immunodeficiency virus with nef deleted in rhesus monkeys. J Virol 2003, 77(12):6823-6835.
67. Whatmore A.M., Cook N., Hall G.A., Sharpe S., Rud E.W., Cranage M.P. Repair and evolution of nef in vivo modulates simian immunodeficiency virus virulence. J Virol 1995, 69(8):5117-5123.
68. Cohen G.B. Mechanism of protection of live attenuated simian immunodeficiency virus: coevolution of viral and immune responses. AIDS 2010, 24(5):637-648. 10.1097/QAD.0b013e328337795a.
69. Clements J.E., Montelaro R.C., Zink M.C., Amedee A.M., Miller S., Trichel A.M., et al. Cross-protective immune responses induced in rhesus macaques by immunization with attenuated macrophage-tropic simian immunodeficiency virus. J Virol 1995, 69:2737-2744.
70. Minor P.D., John A., Ferguson M., Icenogle J.P. Antigenic and molecular evolution of the vaccine strain of type 3 poliovirus during the period of excretion by a primary vaccinee. J Gen Virol 1986, 67(4):693-706.
71. Hammond S.A., Raabe M.L., Issel C.J., Montelaro R.C. Evaluation of antibody parameters as potential correlates of protection or enhancement by experimental vaccines to equine infectious anemia virus. Virology 1999, 262:416-430.